Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R; ABCSG-14. Steger GG, et al. Among authors: kubista e. J Clin Oncol. 2007 May 20;25(15):2012-8. doi: 10.1200/JCO.2006.09.1777. J Clin Oncol. 2007. PMID: 17513805 Clinical Trial.
Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer.
Resch A, Pötter R, Van Limbergen E, Biber E, Klein T, Fellner C, Handl-Zeller L, Langbauer G, Schürer-Waldheim H, Staffen A, Jakesz R, Kubista E, Lehr S, Seitz W. Resch A, et al. Among authors: kubista e. Radiother Oncol. 2002 Apr;63(1):47-58. doi: 10.1016/s0167-8140(02)00022-1. Radiother Oncol. 2002. PMID: 12065103
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H; Austrian Breast and Colorectal Cancer Study Group Trial 5. Jakesz R, et al. Among authors: kubista e. J Clin Oncol. 2002 Dec 15;20(24):4621-7. doi: 10.1200/JCO.2002.09.112. J Clin Oncol. 2002. PMID: 12488405 Clinical Trial.
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H. Schmid M, et al. Among authors: kubista e. J Clin Oncol. 2003 Mar 15;21(6):984-90. doi: 10.1200/JCO.2003.01.138. J Clin Oncol. 2003. PMID: 12637461 Clinical Trial.
Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group.
Jakesz R, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel RC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Taucher S, Seifert M, Hausmaninger H; Austrian Breast & Colorectal Cancer Study Group. Jakesz R, et al. Among authors: kubista e. Ann Surg. 2003 Apr;237(4):556-64. doi: 10.1097/01.SLA.0000059990.43981.4E. Ann Surg. 2003. PMID: 12677153 Free PMC article.
290 results